Get the Stockscreener App
1.065
9.85%
0.091
Mira Pharmaceuticals Inc stock is traded at $1.065, with a volume of 157.33K.
It is up +9.85% in the last 24 hours and up +4.89% over the past month.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
See More
Previous Close:
$0.974
Open:
$0.98
24h Volume:
157.33K
Relative Volume:
1.09
Market Cap:
$44.75M
Revenue:
-
Net Income/Loss:
$-32.00M
P/E Ratio:
-0.7017
EPS:
-1.5178
Net Cash Flow:
$-4.66M
1W Performance:
+10.57%
1M Performance:
+4.89%
6M Performance:
-27.22%
1Y Performance:
-15.09%
1-Day Range:
$0.98
$1.07
1-Week Range:
$0.95
$1.07
52-Week Range:
$0.90
$2.45
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Name
Mira Pharmaceuticals Inc
Sector
Industry
Phone
813-369-5150
Address
1200 BRICKELL AVENUE, MIAMI
Compare MIRA vs LLY, JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
1.065 | 40.93M | 0 | -32.00M | -4.66M | -1.5178 |
LLY
Lilly Eli Co
|
1,089.90 | 949.47B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
231.63 | 554.09B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
213.92 | 376.54B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
121.19 | 295.69B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
187.45 | 290.30B | 60.48B | 10.40B | 8.05B | 3.3297 |
Mira Pharmaceuticals Inc Stock (MIRA) Latest News
MIRA Pharmaceuticals expands Ketamir-2 license to worldwide - Investing.com
MIRA Expands Global Ketamir-2 License for Clinical Development - TipRanks
MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN - ACCESS Newswire
MIRA Pharmaceuticals (MIRA) expands Ketamir-2 license to worldwide IP rights - Stock Titan
Experimental oral chemo nerve damage drug gets IP boost in 10 countries - Stock Titan
MIRA Stock Price, Quote & Chart | MIRA PHARMACEUTICALS INC (NASDAQ:MIRA) - ChartMill
MIRA Pharmaceuticals (MIRA) Q3 2025 Earnings: Why the Beat MattersRising Community Picks - Newser
MIRA Stock Chart | MIRA PHARMACEUTICALS INC (NASDAQ:MIRA) - ChartMill
What's going on with MIRA Pharma stock Tuesday? - MSN
Should You Sell MIRA Pharmaceuticals (MIRA) After -1.24% Drop? 2026-05-15Golden Cross - Newser
MIRA Pharmaceuticals (MIRA) Delivers Q3 2025 Beat — EPS $-0.06 vs $-0.08 ExpectedAnalyst Stock Picks - Newser
MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2 - Black Hills Pioneer
MIRA Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MIRA Pharmaceuticals (MIRA) posts Q1 2026 loss and warns on going concern - Stock Titan
MIRA Pharmaceuticals reports phase 1 results for Ketamir-2 - Investing.com UK
Mira Pharmaceuticals stock gains on Phase 1 trial results By Investing.com - Investing.com South Africa
Mira Pharmaceuticals stock gains on Phase 1 trial results - Investing.com
MIRA Pharmaceuticals reports phase 1 results for Ketamir-2 By Investing.com - Investing.com Canada
Chemo nerve damage has no FDA drugs—MIRA advances new Ketamir-2 pill - Stock Titan
MIRA Pharmaceuticals Reports Positive Phase 1 Ketamir-2 Results - TipRanks
MIRA (MIRA) posts positive Phase 1 data and DEA decision on Ketamir-2 - Stock Titan
MIRA Pharmaceuticals Announces Publication of Preclinical Data on SKNY-1 for Obesity and Nicotine Addiction in International Journal of Molecular Sciences 8910 - Minichart
Mira Pharmaceuticals announces peer-reviewed publication of SKNY-1 preclinical data - Investing.com Nigeria
MIRA publishes preclinical study on obesity drug candidate SKNY-1 By Investing.com - Investing.com South Africa
MIRA publishes preclinical study on obesity drug candidate SKNY-1 - Investing.com
MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate - ACCESS Newswire
MIRA highlights SKNY-1 preclinical data in new publication - TipRanks
Fish study: MIRA test pill cuts weight 30% and dampens nicotine-seeking - Stock Titan
MIRA Pharmaceuticals publishes preclinical SKNY-1 study showing weight loss, lipid benefits - TradingView
MIRA Pharmaceuticals (NASDAQ: MIRA) highlights SKNY-1 preclinical obesity and nicotine data - Stock Titan
Is MIRA Pharmaceuticals (MIRA) stock hiding in plain sight? (Wavering) 2026-05-11Crowd Entry Points - Newser
Number of shareholders of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView
MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies - ACCESS Newswire
MIRA Pharmaceuticals (MIRA) Top Loser | Q3 2025: Profit SurprisesPost Earnings - UBND thành phố Hải Phòng
Should I buy MIRA Pharmaceuticals (MIRA) stock right now | Q3 2025: EPS Exceeds ExpectationsMargin of Safety - UBND thành phố Hải Phòng
MIRA Pharmaceuticals (MIRA) Stock: Momentum Analysis (Momentum Building) 2026-04-16Low Volatility Stocks - Xã Vĩnh Công
Stock List: Research Stocks from Around the World - GuruFocus
Mira Pharmaceuticals Inc Stock (MIRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.12%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):